Kevin Carter
Psychiatric/Mental Health · Cincinnati, OHNPI 1144941329
Payments from drug & device makers
Across 333 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$878
- Neurocrine Biosciences, Inc.$650
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$643
- AbbVie$586
- Otsuka America Pharmaceutical, Inc.$568
- plus $1K from 6 others
What the payments were for
- Food & beverage$5,30895%
- Education$2705%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 41 | $1,053 |
| Johnson & Johnson | 39 | $878 |
| Neurocrine Biosciences, Inc. | 32 | $650 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $643 |
| AbbVie | 66 | $586 |
| Otsuka America Pharmaceutical, Inc. | 34 | $568 |
| Alkermes, Inc. | 23 | $512 |
| Lundbeck LLC | 18 | $287 |
| E.r. Squibb & Sons, L.L.C. | 19 | $172 |
| Indivior Inc. | 7 | $109 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| Luye Pharma (USA) Ltd. | 2 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$121
- INVEGA SUSTENNA$120
- INVEGA TRINZA$120
- ABILIFY ASIMTUFII$117
- ABILIFY MAINTENA$117
- UZEDY$115
- REXULTI$107
How this compares
$5,578 in reported general payments places this provider in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 186 | $610,303 |
| Invega TrinzaPaliperidone Palmitate | 64 | $607,062 |
| Austedo XrDeutetrabenazine | 56 | $556,916 |
| IngrezzaValbenazine Tosylate | 65 | $540,922 |
| AustedoDeutetrabenazine | 60 | $391,680 |
| Abilify MaintenaAripiprazole | 82 | $223,283 |
| Invega HafyeraPaliperidone Palmitate | 11 | $203,649 |
| UzedyRisperidone | 47 | $193,200 |
| AristadaAripiprazole Lauroxil | 59 | $185,249 |
| RexultiBrexpiprazole | 89 | $134,656 |
| VraylarCariprazine Hcl | 79 | $116,953 |
| CaplytaLumateperone Tosylate | 51 | $83,933 |
| LybalviOlanzapine/Samidorphan Malate | 42 | $68,184 |
| PerserisRisperidone | 20 | $57,702 |
| Risperdal ConstaRisperidone Microspheres | 28 | $52,855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $878 | $1,270,219278 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $1,053 | $1,141,796163 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $650 | $540,92265 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $568 | $357,939171 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $512 | $280,744115 claims |
| AbbVieVraylar | $586 | $116,95379 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $643 | $83,93351 claims |
| Indivior Inc.Perseris | $109 | $57,70220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Cincinnati
- Terri PopovitzCincinnati$161K
- Michelle McBrideCincinnati$29K
- Seth FramptonCincinnati$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.